LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19

Photo from wikipedia

Chloroquine (or hydroxychloroquine hereafter referred to as chloroquine), is currently being speculated, amidst growing controversy, as a treatment method for SARSCoV-2 (also known as COVID-19). Exposure to chloroquine for individuals… Click to show full abstract

Chloroquine (or hydroxychloroquine hereafter referred to as chloroquine), is currently being speculated, amidst growing controversy, as a treatment method for SARSCoV-2 (also known as COVID-19). Exposure to chloroquine for individuals with disorders involving red blood cell function, such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, increases their risk for severe hemolytic anemia. In recent clinical trials for COVID-19 treatment with combined chloroquine and azithromycin, scientists have been cautious not to include G6PD-deficient patients. G6PD contributes significantly to the formation of ribose 5-phosphate and the production of NADPH in mature red blood cells. G6PD deficiency is one of the most common enzyme deficiency-related diseases worldwide. Its prevalence ranges between 3.8% and 5.2% in Europe and the United States. The highest reported incidence is in sub-Saharan Africa (8.5%). The disorder is also common in the Mediterranean area (7.2%). A study conducted in Lebanon in 2007 on a group of adult males showed that 22.2% of G6PD-deficient individuals were unaware of their condition. It is indeed well documented that many affected individuals may be asymptomatic and, unless investigated, may remain oblivious of the disease. Environmental factors, including some types of food (such as fava beans in the Mediterranean variants) and medications such as antimalarial drugs that exert excessive oxidative stress on the organism, can elicit an acute hemolytic anemia crisis, which would require blood transfusion. In 1996, screening for G6PD deficiency was introduced as part of the national program for neonatal screening in Lebanon. It has been shown to be highly cost effective, although nationwide implementation has been challenging with only 50% compliance over the total number of newborns. Undiagnosed G6PD deficiency may be challenging for the treatment of COVID-19. Therefore, we recommend testing for G6PD deficiency before initiating chloroquine treatment in patients with COVID-19, in order to prevent unnecessary detrimental consequences. Awareness of a potential adverse outcome should be disseminated in view of the high tendency towards self-medication often described in the Lebanese public. ORCID iD

Keywords: g6pd deficiency; g6pd deficient; chloroquine; deficiency; undiagnosed g6pd

Journal Title: Journal of Medical Screening
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.